



(12) **United States Patent**  
**Machado et al.**

(10) **Patent No.:** **US 9,480,790 B2**  
(45) **Date of Patent:** **Nov. 1, 2016**

(54) **METHODS AND SYSTEMS FOR TREATING ACUTE HEART FAILURE BY NEUROMODULATION**

(71) Applicant: **The Cleveland Clinic Foundation,**  
Cleveland, OH (US)

(72) Inventors: **Sandra Machado**, Beachwood, OH (US); **Marc Penn**, Beachwood, OH (US); **Ali R. Rezai**, Columbus, OH (US)

(73) Assignee: **The Cleveland Clinic Foundation,**  
Cleveland, OH (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/085,311**

(22) Filed: **Nov. 20, 2013**

(65) **Prior Publication Data**

US 2014/0074069 A1 Mar. 13, 2014

**Related U.S. Application Data**

(63) Continuation of application No. 13/654,525, filed on Oct. 18, 2012, now Pat. No. 8,798,738, which is a continuation of application No. 12/185,473, filed on Aug. 4, 2008, now Pat. No. 8,818,501, which is a

(Continued)

(51) **Int. Cl.**

**A61N 1/362** (2006.01)

**A61M 5/142** (2006.01)

**A61N 1/36** (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ..... **A61M 5/14212** (2013.01); **A61N 1/0565** (2013.01); **A61N 1/3627** (2013.01); **A61N 1/36114** (2013.01); **A61N 1/36585** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61N 1/36585**; **A61N 1/0565**; **A61N 1/3627**; **A61N 1/36114**; **A61M 5/14212**

USPC ..... 607/2  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,718,423 A 1/1988 Willis et al.  
4,947,866 A 8/1990 Lessar et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

CA 2 848 781 3/2013  
EP 1 871 469 10/2013

(Continued)

**OTHER PUBLICATIONS**

Ardell et al., "Differential sympathetic regulation of automatic, conductile, and contractile tissue in dog heart," *American Journal of Physiology* (Nov. 1988) 255 (5): H1050-H1059.

(Continued)


*Primary Examiner* — Alyssa M Alter

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(57) **ABSTRACT**

Methods of treating acute heart failure in a patient in need thereof. Methods include inserting a therapy delivery device into a pulmonary artery of the patient and applying a therapy signal to autonomic cardiopulmonary fibers surrounding the pulmonary artery. The therapy signal affects heart contractility more than heart rate. Specifically, the application of the therapy signal increases heart contractility and treats the acute heart failure in the patient. The therapy signal can include electrical or chemical modulation.

**20 Claims, 7 Drawing Sheets**



Related U.S. Application Data					
continuation of application No. 11/951,285, filed on Dec. 5, 2007, now abandoned.			7,277,757 B2	10/2007	Casavant et al.
			7,277,761 B2	10/2007	Shelchuk
			7,279,007 B2 *	10/2007	Nikolic ..... A61B 17/12022 600/37
			7,308,303 B2	12/2007	Whitehurst et al.
			7,389,149 B2	6/2008	Rossing et al.
			7,460,906 B2	12/2008	Libbus
			7,486,991 B2	2/2009	Libbus et al.
			7,499,742 B2	3/2009	Bolea et al.
			7,509,166 B2	3/2009	Libbus
			7,542,800 B2	6/2009	Libbus et al.
			7,547,286 B2	6/2009	Choate
			7,561,923 B2	7/2009	Libbus et al.
			7,616,997 B2	11/2009	Kieval et al.
			7,617,003 B2	11/2009	Caparso et al.
			7,623,926 B2	11/2009	Rossing et al.
			7,630,760 B2	12/2009	Libbus et al.
			7,634,317 B2	12/2009	Ben-David et al.
			7,643,875 B2	1/2010	Heil, Jr. et al.
			7,647,102 B2	1/2010	Routh et al.
			7,658,709 B2	2/2010	Anderson et al.
			7,706,884 B2	4/2010	Libbus
			7,734,348 B2	6/2010	Zhang et al.
			7,765,000 B2	7/2010	Zhang et al.
			7,769,446 B2	8/2010	Moffitt et al.
			7,801,614 B2	9/2010	Rossing et al.
			7,805,194 B1	9/2010	Schecter
			7,813,812 B2	10/2010	Kieval et al.
			7,840,271 B2	11/2010	Kieval et al.
			7,848,812 B2	12/2010	Crowley et al.
			7,869,881 B2	1/2011	Libbus et al.
			7,873,413 B2	1/2011	McCabe et al.
			7,881,782 B2	2/2011	Libbus et al.
			7,885,709 B2	2/2011	Ben-David
			7,885,711 B2	2/2011	Ben-Ezra et al.
			7,904,151 B2	3/2011	Ben-David et al.
			7,908,008 B2	3/2011	Ben-David et al.
			7,925,352 B2	4/2011	Stack et al.
			7,949,400 B2	5/2011	Kieval et al.
			8,000,793 B2	8/2011	Libbus
			8,005,545 B2	8/2011	Ben-David et al.
			8,014,874 B2	9/2011	Rossing et al.
			8,024,050 B2	9/2011	Libbus et al.
			8,027,724 B2	9/2011	Wei et al.
			8,032,215 B2	10/2011	Libbus et al.
			8,060,206 B2	11/2011	Kieval et al.
			8,086,314 B1	12/2011	Kieval
			8,121,693 B2	2/2012	Libbus
			8,126,560 B2	2/2012	Schiener et al.
			8,131,373 B2	3/2012	Libbus
			8,145,304 B2	3/2012	Moffitt et al.
			8,150,521 B2	4/2012	Crowley et al.
			8,155,744 B2	4/2012	Rezaei
			8,175,705 B2	5/2012	Libbus
			8,195,289 B2	6/2012	Heil, Jr. et al.
			8,195,290 B2	6/2012	Brockway et al.
			8,204,591 B2	6/2012	Ben-David et al.
			8,229,564 B2	7/2012	Rezaei
			8,244,355 B2	8/2012	Bennett et al.
			8,249,706 B2	8/2012	Koh
			8,290,595 B2	10/2012	Kieval et al.
			8,369,954 B2	2/2013	Stack et al.
			8,386,053 B2	2/2013	Kornet
			8,386,056 B2	2/2013	Ben-David et al.
			8,401,672 B2	3/2013	Libbus et al.
			8,406,877 B2	3/2013	Smith et al.
			8,412,326 B2	4/2013	Arcot-Krishnamurthy et al.
			8,417,354 B2	4/2013	Zhang et al.
			8,428,730 B2	4/2013	Stack et al.
			8,437,867 B2	5/2013	Murney et al.
			8,452,398 B2	5/2013	Libbus et al.
			8,473,076 B2	6/2013	Libbus et al.
			8,498,703 B2	7/2013	Spinelli et al.
			8,538,535 B2	9/2013	Gross et al.
			8,583,236 B2	11/2013	Kieval et al.
			8,606,359 B2	12/2013	Rossing et al.
			8,620,426 B2	12/2013	Moffitt et al.
			8,626,290 B2	1/2014	Dagan et al.
			8,626,299 B2	1/2014	Gross et al.
(60) Provisional application No. 60/873,021, filed on Dec. 6, 2006.					
(51) Int. Cl.					
A61N 1/05 (2006.01)					
A61N 1/365 (2006.01)					
(56) References Cited					
U.S. PATENT DOCUMENTS					
4,950,227 A	8/1990	Savin et al.			
5,067,957 A	11/1991	Jervis			
5,156,154 A *	10/1992	Valenta et al. ....	600/455		
5,190,546 A	3/1993	Jervis			
5,197,978 A	3/1993	Hess			
5,213,098 A	5/1993	Bennett et al.			
5,224,491 A	7/1993	Mehra			
5,259,387 A	11/1993	DePinto			
5,336,244 A	8/1994	Weijand			
5,345,936 A	9/1994	Pomeranz et al.			
5,365,926 A	11/1994	Desai			
5,423,881 A	6/1995	Breyen et al.			
5,431,649 A *	7/1995	Mulier .....	A61B 18/1477 600/374		
5,564,434 A	10/1996	Halperin et al.			
5,711,316 A	1/1998	Elsberry et al.			
5,725,570 A	3/1998	Heath			
5,755,766 A	5/1998	Chastain et al.			
5,782,239 A	7/1998	Webster			
5,853,411 A	12/1998	Whayne et al.			
5,948,007 A	9/1999	Starkebaum et al.			
5,954,761 A	9/1999	Machek et al.			
5,968,040 A	10/1999	Swanson et al.			
5,997,563 A	12/1999	Kretzers			
6,036,697 A	3/2000	DiCaprio			
6,038,480 A	3/2000	Hrdlicka et al.			
6,058,331 A	5/2000	King			
6,059,810 A	5/2000	Brown et al.			
6,071,308 A	6/2000	Ballou et al.			
6,136,021 A	10/2000	Tockman et al.			
6,161,029 A	12/2000	Spreigl et al.			
6,231,516 B1	5/2001	Keilman et al.			
6,241,724 B1	6/2001	Fleischman et al.			
6,266,564 B1	7/2001	Hill et al.			
6,292,695 B1	9/2001	Webster et al.			
6,295,475 B1	9/2001	Morgan			
6,319,241 B1	11/2001	King et al.			
6,353,762 B1	3/2002	Baudino et al.			
6,447,478 B1	9/2002	Maynard			
6,473,653 B1	10/2002	Schallhorn et al.			
6,522,926 B1	2/2003	Kieval et al.			
6,542,774 B2	4/2003	Hill et al.			
6,547,788 B1	4/2003	Maguire et al.			
6,564,096 B2	5/2003	Mest			
6,574,492 B1	6/2003	Ben-Haim et al.			
6,669,693 B2	12/2003	Friedman			
6,738,655 B1	5/2004	Sen et al.			
6,740,113 B2	5/2004	Vrba			
6,748,271 B2	6/2004	Spinelli et al.			
6,754,532 B1	6/2004	Ferek-Petric			
RE38,654 E	11/2004	Hill et al.			
6,832,478 B2	12/2004	Anderson et al.			
6,850,801 B2	2/2005	Kieval et al.			
6,912,419 B2	6/2005	Hill et al.			
6,985,774 B2	1/2006	Kieval et al.			
6,993,385 B1	1/2006	Routh et al.			
7,072,720 B2	7/2006	Puskas			
7,092,759 B2	8/2006	Nehls et al.			
7,096,070 B1	8/2006	Jenkins et al.			
7,158,832 B2	1/2007	Kieval et al.			
7,231,260 B2	6/2007	Wallace et al.			
7,260,431 B2	8/2007	Libbus et al.			

(56)

**References Cited****U.S. PATENT DOCUMENTS**

8,634,921	B2	1/2014	Chavan et al.
8,639,332	B2	1/2014	Kuhn et al.
8,682,430	B2	3/2014	Libbus et al.
8,682,434	B2	3/2014	Libbus
8,712,531	B2	4/2014	Kieval et al.
8,718,789	B2	5/2014	Bolea et al.
8,725,250	B2	5/2014	Brockway et al.
8,755,907	B2	6/2014	Kieval et al.
8,788,066	B2	7/2014	Cates et al.
8,798,738	B2	8/2014	Machado et al.
8,805,501	B2	8/2014	Libbus
8,818,501	B2	8/2014	Machado et al.
8,838,246	B2	9/2014	Kieval
8,855,783	B2	10/2014	Dagan et al.
8,880,190	B2	11/2014	Kieval et al.
8,918,172	B2	12/2014	Moffitt et al.
8,929,990	B2	1/2015	Moffitt et al.
8,934,968	B2	1/2015	Whitehurst et al.
8,972,015	B2	3/2015	Stack et al.
8,983,601	B2	3/2015	Fukamachi et al.
9,005,100	B2	4/2015	Gnanashanmugam et al.
9,005,106	B2	4/2015	Gross et al.
9,031,650	B2	5/2015	McCabe et al.
9,031,669	B2	5/2015	Zhang et al.
9,044,609	B2	6/2015	Bolea et al.
9,067,071	B2	6/2015	Sanders et al.
9,126,048	B2	9/2015	Ransbury et al.
9,149,639	B2	10/2015	Zhang et al.
9,168,094	B2	10/2015	Lee et al.
9,216,289	B2	12/2015	Libbus et al.
2003/0114878	A1	6/2003	Diederich et al.
2004/0143254	A1	7/2004	Vanney et al.
2004/0172079	A1	9/2004	Chinchoy
2004/0260375	A1	12/2004	Zhang et al.
2005/0154321	A1*	7/2005	Wolinsky ..... A61B 5/0031 600/486
2005/0251239	A1*	11/2005	Wallace ..... A61N 1/057 607/126
2006/0058597	A1	3/2006	Machado et al.
2006/0074453	A1	4/2006	Kieval et al.
2006/0085046	A1	4/2006	Rezai et al.
2006/0206159	A1	9/2006	Moffitt et al.
2006/0229677	A1	10/2006	Moffitt et al.
2006/0259084	A1	11/2006	Zhang et al.
2006/0259085	A1	11/2006	Zhang et al.
2007/0135875	A1	6/2007	Demarais et al.
2008/0082137	A1	4/2008	Kieval et al.
2008/0167693	A1	7/2008	Kieval et al.
2008/0312711	A1	12/2008	Struble
2009/0018596	A1	1/2009	Kieval
2009/0163912	A1	6/2009	Wang et al.
2009/0228078	A1	9/2009	Zhang et al.
2009/0276022	A1	11/2009	Burnes et al.
2010/0222832	A1	9/2010	Zhang et al.
2011/0106199	A1	5/2011	McCabe et al.
2011/0160790	A1	6/2011	Stegemann et al.
2012/0310304	A1	12/2012	Brockway et al.
2013/0110208	A1	5/2013	Inagaki et al.
2013/0218221	A1	8/2013	Zhang et al.
2013/0253616	A1	9/2013	Libbus et al.
2013/0331919	A1	12/2013	Zhang et al.
2013/0338748	A1	12/2013	Dagan
2014/0052208	A1	2/2014	Ransbury et al.
2014/0114377	A1	4/2014	Dagan et al.

2014/0277235	A1	9/2014	An et al.
2014/0324115	A1	10/2014	Ziegler et al.
2015/0039058	A1	2/2015	Masson et al.
2015/0134019	A1	5/2015	Moffitt et al.
2015/0142011	A1	5/2015	Cates et al.
2015/0151121	A1	6/2015	Dagan et al.
2015/0238763	A1	8/2015	Bolea et al.

**FOREIGN PATENT DOCUMENTS**

EP	2 316 525	1/2016
WO	WO 97/24983	7/1997
WO	WO 2006/007048	1/2006
WO	WO 2008/054448	5/2008
WO	WO 2009/135083	11/2009
WO	WO 2012/149511	11/2012
WO	WO 2015/179634	11/2015
WO	WO 2016/040037	3/2016
WO	WO 2016/040038	3/2016
WO	WO 2016/111940	7/2016

**OTHER PUBLICATIONS**

Casadei, "Vagal control of myocardial . . . in humans," The Physiological Society (Mar. 2001): 817-823.

Ferrari et al., "Vagus nerve stimulation . . . future directions," Heart Fail Rev. (2011) 16: 195-203.

Klein et al., "Vagus nerve stimulation . . . heart failure," Cardiology Journal (2010) 17 (6): 638-643.

Koizumi et al., "Functional significance of coactivation . . .," National Academy of Sciences (Mar. 1982) 79 (6): 2116-2120.

Meyer et al., "Augmentation of left ventricular . . .," Americ. Heart Assoc. (2010): 1286-1294.

Murphy, "Preliminary observations of the effects of simulation of . . . in man," CA Journal of Phys. And Pharmac (Jun. 1985). 63 (6): 649-655.

Randall et al., "Regional cardiac distribution . . .," Federation Proceedings (Jul.-Aug. 1972) 31 (4): 1199-1208.

Randall, "Augmentor action to the sympathetic . . .," Journal of Applied Physiology (Jul. 1960) 15 (4): 629-631.

Tripodskiadis et al., "Sympathetic nervous . . . failure," Journal of Amer. Coll. of Cardiology (Nov. 3, 2009) 54 (19): 1747-1762.

Zarse, "Selective increase . . . sympathetic tone," Journal of Amer. Coll. of Cardiology (2005) 46 (7): 1355-1359.

International Search Report for related International Application No. PCT/US2007/025166 mailed on Mar. 10, 2008.

Written Opinion for related International Application No. PCT/US2007/025166 mailed on Mar. 10, 2008.

International Preliminary Report on Patentability for related International Application No. PCT/US2007/025166 mailed on Jun. 10, 2009.

Extended European Search Report for EP 07853308.0 dated Apr. 16, 2010.

Rudski et al., "Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography", J Am Soc Echocardiogr, 2010, vol. 23, pp. 685-713.

Lawo et al., "Electrical Signals Applied During the Absolute Refractory Period", JACC, Dec. 20, 2005, vol. 46, No. 21, pp. 2229-2236.

\* cited by examiner




FIG. 1




FIG.2




FIG. 3




FIG. 4




FIG. 5






FIG.6




FIG.7

1

## METHODS AND SYSTEMS FOR TREATING ACUTE HEART FAILURE BY NEUROMODULATION

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 13/654,525, filed on Oct. 18, 2012 and issued as U.S. Pat. No. 8,798,738 on Aug. 5, 2014, which is a continuation of U.S. application Ser. No. 12/185,473, filed on Aug. 4, 2008 and issued as U.S. Pat. No. 8,818,501 on Aug. 26, 2014, which is a continuation of U.S. application Ser. No. 11/951,285, filed on Dec. 5, 2007, which claims priority to U.S. Provisional Application No. 60/873,021, filed on Dec. 6, 2006, each of U.S. application Ser. No. 12/185,473, U.S. application Ser. No. 11/951,285, and U.S. Provisional Application No. 60/873,021 being incorporated by reference in its entirety herein. The present application is also related to U.S. application Ser. No. 11/222,766, filed on Sep. 12, 2005, which is incorporated by reference herein.

### FIELD OF THE INVENTION

The present invention relates to methods and systems for treating acute heart failure by electrically modulating autonomic cardiopulmonary fibers.

### BACKGROUND OF THE INVENTION

Diseases or injuries causing or resulting in acute heart failure are widespread. The goals of therapy in acute heart failure are often to correct the hemodynamic instability and address decompensation in order to increase patient mortality. One treatment option for acute heart failure is the administration of inotropic agents, such as dopamine and dobutamine. However, inotropic agents have both chronotropic and inotropic effects and characteristically increase heart contractility at the expense of significant increments in oxygen consumption secondary to elevations in heart rate. As a result, although these inotropic agents increase myocardial contractility and improve hemodynamics, clinical trials have consistently demonstrated excess mortality caused by cardiac arrhythmias and increase in the myocardium consumption.

As such, there is a need for a method of selectively and locally treating acute heart failure and otherwise achieving hemodynamic control without causing untoward systemic effect.

### SUMMARY OF THE INVENTION

The present invention provides methods for treating medical conditions by transvascular neuromodulation of a target site of an autonomic nervous system. The methods of the present invention for treating medical conditions encompass neuromodulation of any combination of one or more target sites of the autonomic nervous system. Non-limiting examples of medical conditions that can be treated according to the present invention include cardiovascular medical conditions.

In an embodiment, the present invention provides a method of treating acute heart failure in a patient in need thereof comprising inserting a delivery device into a pulmonary artery and positioning the delivery device at a pulmonary trunk of the pulmonary artery. The method also comprises applying a therapy signal to at least one sym-

2

thetic cardiopulmonary fiber surrounding the pulmonary trunk to treat the acute heart failure. The at least one sympathetic cardiopulmonary fiber affects heart contractility more than heart rate.

In another embodiment, the present invention provides a system for treating acute heart failure comprising a delivery device for positioning in the pulmonary artery at the pulmonary trunk. The system further includes a controller in communication with the delivery device for enabling the delivery device to apply a therapy signal to at least one sympathetic cardiopulmonary fiber surrounding the pulmonary trunk to treat acute heart failure. The at least one sympathetic cardiopulmonary fiber affects heart contractility more than heart rate.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic illustration of the heart and surrounding areas, showing the stimulation sites according to the present invention.

FIG. 2 is a schematic illustration of the specific nerves where stimulation can be applied according to an embodiment of the present invention.

FIG. 3 is an electrical delivery device to be positioned within the pulmonary artery according to an embodiment of the present invention.

FIG. 4 is a schematic illustration of the components used in a controller of an embodiment of a system of the present invention.

FIG. 5 is a block diagram of an algorithm to determine action taken by a controller microprocessor in response to sensor input according to an embodiment of a system of the present invention.

FIG. 6 is a graph showing the peak and average contractility percentage changes in dogs treated with electrical modulation according to an embodiment of the present invention and as described in Example 1.

FIG. 7 is a graph showing the average percentage change in contractility compared to heart rate in dogs treated with electrical modulation according to an embodiment of the present invention and as described in Example 1.

### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for treating medical conditions by transvascular neuromodulation of a target site of an autonomic nervous system. The methods of the present invention for treating medical conditions encompass neuromodulation of any combination of one or more target sites of the autonomic nervous system. Non-limiting examples of medical conditions that can be treated according to the present invention include cardiovascular medical conditions.

With respect to treating cardiovascular medical conditions, such medical conditions can involve any medical conditions related to the components of the cardiovascular system such as, for example, the heart and aorta. Non-limiting examples of cardiovascular conditions include post-infarction rehabilitation, shock (hypovolemic, septic, neurogenic), valvular disease, heart failure, angina, microvascular ischemia, myocardial contractility disorder, cardiomyopathy, hypertension including pulmonary hypertension and systemic hypertension, orthopnea, dyspnea, orthostatic hypotension, dysautonomia, syncope, vasovagal reflex, carotid sinus hypersensitivity, pericardial effusion, heart failure, and cardiac structural abnormalities such as

septal defects and wall aneurysms. Non-limiting examples of vessels into which therapy delivery devices, according to the present invention, are positioned to access autonomic target sites innervating components of the cardiovascular system are the carotid arteries; aorta; superior vena cava; inferior vena cava; pulmonary veins and arteries; carotid arteries; and subclavian arteries and veins. In a preferred embodiment, a therapy delivery device is used in conjunction with a pulmonary artery catheter, such as a Swan-Ganz type pulmonary artery catheter to deliver transvascular neuromodulation via the pulmonary artery to an autonomic target site to treat a cardiovascular condition according to the present invention. Specifically, in this preferred embodiment, a therapy delivery device is housed within one of the multiple vessels of a pulmonary artery catheter.

The present invention provides systems and methods for treating acute heart failure, also known as decompensated heart failure, by modulating at least one sympathetic cardiopulmonary fiber that affects heart contractility more than heart rate. In a preferred embodiment, a plurality of sympathetic cardiopulmonary fibers is modulated that collectively affect heart contractility more than heart rate. The fibers can be modulated by chemical and/or electrical modulation (including ablation) and the modulation includes stimulating and/or inhibiting the fibers. In the case of chemical modulation, bioactive agents may be used, including neurotransmitter mimics; neuropeptides; hormones; pro-hormones; antagonists, agonists, reuptake inhibitors, or degrading enzymes thereof; peptides; proteins; therapeutic agents; amino acids; nucleic acids; stem cells, or any combination thereof and may be delivered by a slow release matrix or drug pump.

According to the methods of the present invention, a delivery device, which can be an electrode in the case of electrical modulation, or a drug delivery device (e.g., a catheter) in the case of chemical modulation, is inserted into the pulmonary artery and positioned at a location within the pulmonary trunk such that activation of the delivery device at that location results in selective modulation of sympathetic cardiopulmonary fibers. Specifically, the sympathetic cardiopulmonary fibers that are modulated collectively affect heart contractility more than heart rate. Preferably, the delivery device is positioned at a site within the pulmonary artery such that activation of the delivery device results in the greatest effect on heart contractility and the least effect on heart rate and/or oxygen consumption compared to activation of the delivery device at any other site in the pulmonary artery. In certain embodiments, the effect on heart contractility is to increase heart contractility. In certain embodiments, electrical modulation is provided in combination with chemical modulation. In such embodiments, the present invention also provides systems that include electrical and chemical delivery devices.

FIG. 1 is a schematic illustration of the heart 10 and the pulmonary artery 20. As is known in the art, the pulmonary artery includes the pulmonary trunk 30, which begins at the base of the right ventricle; the right pulmonary artery 40; and the left pulmonary artery 50. The pulmonary trunk is short and wide, approximately 5 cm (2 inches) in length and 3 cm (1.2 inches) in diameter. In a preferred embodiment, an electrical delivery device is activated at the site 60 of the pulmonary trunk 30 that is at the base of the T-shape (circled in FIG. 1) formed by the left branch and right branch of the pulmonary artery.

The neuromodulation of the present invention is accomplished by applying a therapy signal, such as an electrical and/or chemical signal to the pulmonary trunk, such as at

least one of the anterior wall, the posterior wall, the superior wall, and the lateral wall. The therapy signal is thereby applied to the sympathetic cardiopulmonary fibers, or nerves, surrounding the pulmonary trunk. These sympathetic fibers can include the right sympathetic cardiopulmonary nerves and the left sympathetic cardiopulmonary nerves, as illustrated in FIG. 2. The right sympathetic cardiopulmonary nerves include the right dorsal medial cardiopulmonary nerve 110 and the right dorsal lateral cardiopulmonary nerve 112. The left sympathetic cardiopulmonary nerves include the left ventral cardiopulmonary nerve 114, the left dorsal medial cardiopulmonary nerve 116, the left dorsal lateral cardiopulmonary nerve 118, and the left stellate cardiopulmonary nerve 200.

The delivery device can be introduced by any route or means to access the pulmonary artery. For example, the delivery device can be introduced through a large vein, such as the internal jugular, subclavian, or femoral veins or an artery and can be threaded, perhaps with the aid of fluoroscopy, into the pulmonary artery and placed at the pulmonary trunk.

The present invention also provides systems for treating acute heart failure. In an embodiment, the system includes a delivery device, which can be an electrical and/or chemical delivery device (such as an electrode and/or catheter) for positioning in the pulmonary artery at the pulmonary trunk and a controller, such as a pulse generator when an electrical delivery device is used and a drug pump when a chemical delivery device is used, in communication with the delivery device for enabling the delivery device to apply a therapy signal to at least one sympathetic cardiopulmonary fiber surrounding the pulmonary trunk to treat acute heart failure, wherein said at least one sympathetic cardiopulmonary fiber affects heart contractility more than heart rate. In certain embodiments, the system further includes a sensor for measuring cardiac parameters and generating a sensor signal.

FIG. 3 provides an illustration of an exemplary electrical delivery device that can be used in accordance with an embodiment of a system of the present invention when electrical modulation is desired. The electrical delivery device is an intraluminal electrode assembly 230 that can provide intimate contact with a vessel wall. The intraluminal electrode assembly 230 includes a plurality of insulated electrical conductors 236, each conductor 236 connected to a preferably cylindrical electrode 232 disposed annularly thereon. There can be any number of conductors 236 having any number of electrodes 232 disposed thereon, but in a preferred embodiment, there are eight conductors with each conductor have one electrode disposed thereon. A frame 234 is connected to the ends of the plurality of insulated electrical conductors 236. In certain embodiments, electrodes 232 serve as cathodes and frame 234 serves as an anode.

Frame 234 is collapsible for fitting within a catheter lumen 240 during insertion into the body. Specifically, frame 234 has a first collapsed configuration smaller than the diameter of lumen 240 and, when deployed, a second radially expanded configuration designed to contact the vessel wall against which intraluminal electrode assembly 230 is positioned. Frame 234 is preferably fabricated from a super-elastic material, such as nitinol, for example, which allows frame 234 to return to its expanded state when deployed from lumen 240 and assume a collapsed state when retracted back into lumen 240. In a preferred embodiment, the distal end of frame 234 has an open stent-like configuration, preferably a plurality of diamond shapes 238 connected to each other by connector 242, creating a closed

circular loop. Although electrodes **232** can be mounted at any position on insulated conductor **236**, they are preferably mounted near frame **234**.

In a preferred embodiment, lumen **240** is one lumen of a multi-lumen pulmonary catheter as described in more detail in co-pending application Ser. No. 11/222,774, filed on Sep. 12, 2005.

Electrical delivery device **230** is connected via a stimulation lead/catheter to a controller (not shown). The electrical delivery device may be placed temporarily in the pulmonary trunk adjacent to a sympathetic cardiopulmonary fiber. The controller of an embodiment of a system of the present invention is used to operate and supply power to the delivery device and enable the delivery device to deliver a therapy signal to a sympathetic cardiopulmonary fiber. The controller may be powered by a battery (which can be rechargeable), an external power supply, or a fuel cell. The controller may also be integral with the delivery device (such as a single stimulation lead/power generator or a single catheter/drug delivery pump). In the case of electrical modulation, the controller may change the output to the electrode by way of polarity, pulse width, amplitude, frequency, voltage, current, intensity, duration, wavelength, and/or waveform. The controller may operate any number or combination of electrodes. In the case of chemical modulation, the controller may change the dosage, timing or other parameters of drug delivery. The controller may operate any number of combination of drug ports. The controller can be external to the patient's body for use by the attending physician to program the controller and to monitor its performance or internal to the patient's body.

In the case of electrical modulation, the controller activates the electrical delivery device to initiate or adjust application of an electrical signal including terminating, increasing, decreasing, or changing the rate or pattern of a pulsing parameter. The controller also enables an electrical delivery device to deliver an electrical signal that may be episodic, continuous, phasic, in clusters, intermittent, upon demand by the patient or medical personnel, or preprogrammed to respond to a sensor. Preferably, the oscillating electrical signal is operated at a voltage between about 0.1 microvolts to about 20 V. More preferably, the oscillating electrical signal is operated at a voltage between about 1 V to about 15 V. For microstimulation, it is preferable to stimulate within the range of 0.1 microvolts to about 1 V. Preferably, the electric signal source is operated at a frequency range between about 2 Hz to about 2500 Hz. More preferably, the electric signal source is operated at a frequency range between about 2 Hz to about 200 Hz. Preferably, the pulse width of the oscillating electrical signal is between about 10 microseconds to about 1,000 microseconds. More preferably, the pulse width of the oscillating electrical signal is between about 50 microseconds to about 500 microseconds. Preferably, the application of the oscillating electrical signal is: monopolar when the electrode is monopolar; bipolar when the electrode is bipolar; and multipolar when the electrode is multipolar. The waveform may be, for example, biphasic square wave, sine wave, or other electrically safe and feasible combinations. The electrical signal may be applied to multiple target sites simultaneously or sequentially.

In the case of chemical modulation, the controller can enable a drug port to deliver a bioactive agent to the target site. Where chemical and electrical modulation are both used, the controller can also coordinate delivery of the bioactive agent with the electrical neuromodulation (e.g., delivery of the bioactive agent prior to, concurrent with, or

subsequent to electrical neuromodulation). The delivery of the bioactive agent may be continuous, intermittent, chronic, phasic, or episodic.

An open-loop or closed-loop feedback mechanism may be used in conjunction with any of the methods of the present invention. In an open-loop feedback mechanism, a professional can monitor cardiac parameters of the patient and accordingly adjust the therapy signal applied to sympathetic cardiopulmonary fiber. Non-limiting examples of cardiac parameters monitored include arterial blood pressure, central venous pressure, capillary pressure, systolic pressure variation, arterial blood gases, cardiac output, systemic vascular resistance, pulmonary artery wedge pressure, and mixed venous oxygen saturation. Cardiac parameters can be monitored by an electrocardiogram, invasive hemodynamics, an echocardiogram, or blood pressure measurement or other devices known in the art to measure cardiac function. Other parameters such as body temperature and respiratory rate can also be monitored and processed as part of the feedback mechanism.

In a closed-loop feedback mechanism, the cardiac parameters are processed by at least one sensor and the neuromodulation is continuously adjusted according to the output generated by the sensor. Specifically, a sensor detects a cardiac parameter and generates a sensor signal. The sensor signal is processed by a sensor signal processor that provides a control signal to a signal generator. The signal generator, in turn, generates a response to the control signal by activating or adjusting the therapy signal applied by the delivery device to a sympathetic cardiopulmonary fiber. The control signal may be an indication to initiate, terminate, increase, decrease or change the rate or pattern of a pulsing or dosing parameter of the neuromodulation and the response to the control signal can be the respective initiation, termination, increase, decrease or change in rate or pattern of the respective pulsing or dosing parameter. The processing of closed-loop feedback systems for electrical neuromodulation is described in more detail in respective U.S. Pat. Nos. 6,058,331 and 5,711,316, both of which are incorporated by reference herein.

Closed-loop electrical modulation, according to the present invention can be achieved by a modified form of an implantable SOLETRA, KINETRA, RESTORE, or SYNERGY signal generator available from Medtronic, Minneapolis, Minn. as disclosed in U.S. Pat. No. 6,353,762, the teaching of which is incorporated herein in its entirety, a controller as described in FIG. 4, or utilization of CIO DAS 08 and CIO-DAC 16 I processing boards and an IBM compatible computer available from Measurement Computing, Middleboro, Mass. with Visual Basic software for programming of algorithms. Such controllers can be modified for external, as opposed to implantable use. With reference to FIG. 4, an illustration of a non-limiting example of a controller comprising a microprocessor **76** such as an MSP430 microprocessor from Texas Instruments Technology, analog to digital converter **82** such as AD7714 from Analog Devices Corp., pulse generator **84** such as CD1877 from Harris Corporation, pulse width control **86**, lead driver **90**, digital to analog converter **88** such as MAX538 from Maxim Corporation, power supply **72**, memory **74**, and communications port or telemetry chip **70** are shown. Optionally, a digital signal processor **92** is used for signal conditioning and filtering. Input leads **78** and **80** and output leads **91** and **93** are also illustrated. Additional stimulation leads, sensors, and chemical delivery devices may be added to the controller as required. As a non-limiting example, inputs from sensors, such as a pulmonary artery wedge

pressure sensor, are input to analog to digital converter **82**. Microprocessor **76** receiving the sensor inputs uses algorithms to analyze the cardiac parameter of the patient and using PID, Fuzzy logic, or other algorithms, computes an output to pulse generator drivers **90** and **94**, respectively, to neuromodulate the target site where the delivery devices are placed. The output of analog to digital converter **82** is connected to microprocessor **76** through a peripheral bus including address, data and control lines. Microprocessor **76** processes the sensor data in different ways depending on the type of transducer in use. When the signal on the sensor indicates a cardiac parameter outside of threshold values, for example reduced pulmonary artery wedge pressure, programmed by the clinician and stored in a memory, the therapy signal applied through output drivers **90** and **94** of the controller will be adjusted. The output voltage or current from the controller are then generated in an appropriately configured form (voltage, current, frequency), and applied to the one or more delivery devices placed at the target site for a prescribed time period to elevated the pulmonary artery wedge pressure. If the patient's pulmonary artery wedge pressure as monitored by the system is not outside of the normal threshold limits, or if the controller output (after it has timed out) has resulted in a correction of the pulmonary artery wedge pressure to within a predetermined threshold range, no further therapy signal is applied to the target site and the controller continues to monitor the patient via the sensors. A block diagram of an algorithm which may be used in the present invention is shown in FIG. 3.

Referring to FIG. 5, suitably conditioned and converted sensor data **98** can be input to the algorithm in block **100**. The program can compute at least one value of at least one cardiac parameter such as, for example pulmonary artery wedge pressure or cardiac output, and compares the measured value of the cardiac parameter to a pre-determined range of values, which is determined in advance to be the desired therapeutic range of values. This range can be programmed into the microprocessor via the telemetry or communications port of the controller. The algorithm can compare **110**, and then can determine whether or not the measured value lies outside the pre-determined range of values **120**. If the measured cardiac parameter value is not outside the pre-determined range of values, the program can continue to monitor the sensors and reiterates the comparison part of the algorithm. If the measured cardiac parameter value is outside of the pre-determined range of values, a determination or comparison can be made **130**, as to whether the value is too high or too low compared with the pre-determined range. If the cardiac parameter value is too high, an adjustment to the delivery device can be made **150**, to lower the cardiac parameter value of the patient by calculating an output signal for the pulse generator or drug delivery device to deliver a sufficient amount of the pharmaceutical or electrical modulation to lower the cardiac parameter of the patient. The algorithm can continue to monitor the cardiac parameter following the adjustment. If the cardiac parameter value is too low then an adjustment to the delivery device can be made **140**, to raise the cardiac parameter value by calculating an output signal for the pulse generator or drug delivery device to deliver a sufficient amount of a pharmaceutical or electrical modulation to raise the cardiac parameter value of the patient. The algorithm can continue to monitor the cardiac parameter of the patient **100**, following the adjustment. The amount of adjustment made may be determined by proportional integral derivative algorithms of by implementation of Fuzzy logic rules. Of course,

the above-described sensory system is just exemplary and other ways of processing sensory data can be utilized.

With respect to the control of specific electrical parameters, the stimulus pulse frequency may be controlled by programming a value to a programmable frequency generator using the bus of the controller. The programmable frequency generator can provide an interrupt signal to the microprocessor through an interrupt line when each stimulus pulse is to be generated. The frequency generator may be implemented by model CDP1878 sold by Harris Corporation. The amplitude for each stimulus pulse may be programmed to a digital to analog converter using the controller's bus. The analog output can be conveyed through a conductor to an output driver circuit to control stimulus amplitude. The microprocessor of the controller may also program a pulse width control module using the bus. The pulse width control can provide an enabling pulse of duration equal to the pulse width via a conductor. Pulses with the selected characteristics can then be delivered from signal generator through a cable and lead to the target site or to a device such as a proportional valve or pump. The microprocessor can execute an algorithm to provide modulation of a target site with closed loop feedback control. For some types of sensors, a microprocessor and analog to digital converter will not be necessary. The output from sensor can be filtered by an appropriate electronic filter in order to provide a control signal for signal generator. An example of such a filter is found in U.S. Pat. No. 5,259,387 "Muscle Artifact Filter," issued to Victor de Pinto on Nov. 9, 1993, incorporated herein by reference in its entirety. Of course, the specific electrical and/or chemical parameters can be controlled in other ways as well.

## EXAMPLES

### Example 1

Six open-chest dogs were instrumented with a left ventricle conductance catheter and an aortic flow probe. Modified electrode-catheters were placed inside the pulmonary artery under echocardiographic and fluoroscopic guidance in five dogs. In the last dog, a stent-based electrode, as illustrated in FIG. 3, was used. Stimulation was applied at 20 Hz, 0.4 ms, and 15-25 mA. The corresponding hemodynamic effects are reported as averages of 30 second periods of continuous recording.

Pressure variation in the left ventricle over time increased in all dogs. The average increment was 25.7% (+/-11.8) and the average of maximum increase variation was 28.3 (+/-8.9). Emax was measured in the last animal, showing a 45% increase. The average reduction of RR interval during stimulation was 3.3% (+/-10.4).

Therefore, electrical modulation via a pulmonary artery catheter can produce positive inotropic effects with minimal changes in heart rate.

### Example 2

Eight open-chest dogs are instrumented with a left ventricle conductance catheter and an aortic flow probe. Modified electrode-catheters are placed inside the pulmonary artery under echocardiographic and fluoroscopic guidance in five dogs. In three dogs, a stent-based electrode, as illustrated in FIG. 3, is used. Stimulation is applied at 20 Hz, 0.4 ms, and 15-25 mA. The corresponding hemodynamic effects are reported as averages of 30 second periods of continuous recording.

FIG. 6 shows the percentage changes in  $dp/dt$  max for each dog when compared to the baseline. Specifically, FIG. 6 shows the peak  $dp/dt$  max % change achieved during modulation and the average % change in  $dp/dt$  max in a period of 30 seconds. There is significant increase in  $dp/dt$  max during modulation ranging from 21-22 to 44-45%. However, there is no significant change between the average and the peak value.

FIG. 7 compares the average  $dp/dt$  max to the percentage increase in heart rate in the eight dogs. As shown, the heart rate increase is minimal when compared to increase in heart contractility ( $dp/dt$  max).

The foregoing description and examples has been set forth merely to illustrate the invention and are not intended as being limiting. Each of the disclosed aspects and embodiments of the present invention may be considered individually or in combination with other aspects, embodiments, and variations of the invention. In addition, unless otherwise specified, none of the steps of the methods of the present invention are confined to any particular order of performance. Modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art and such modifications are within the scope of the present invention. Furthermore, all references cited herein are incorporated by reference in their entirety.

The invention claimed is:

1. A therapy delivery device for treating cardiovascular medical conditions, comprising:
  - a plurality of insulated electrical conductors each having a distal end;
  - a plurality of electrodes, each said electrode of the plurality of electrodes being in electrical communication with one said insulated electrical conductor of plurality of insulated electrical conductors;
  - a collapsible frame connected to the distal ends of the plurality of insulated electrical conductors, the collapsible frame defining a closed circular loop joined by a plurality of connectors, the plurality of electrodes proximal to the collapsible frame;
  - the collapsible frame configured to expand from a first position when positioned within a catheter lumen to a second position when positioned outside the catheter lumen and collapses back to the first position within the catheter lumen when retracted back into the catheter lumen, where in use the plurality of electrodes are configured to substantially contact one or more portions of a pulmonary artery of a subject and to deliver a therapy signal to at least one autonomic fiber in proximity to the pulmonary artery to affect one or more of cardiac output and hemodynamics, wherein the therapy signal can, when in use, both increase heart contractility and affect heart contractility more than heart rate;
  - a controller in electrical communication with one or more of the plurality of conductors and plurality of electrodes; and
  - one or more sensors for measuring biological parameters and generating one or more sensor signals, the one or more sensors operationally connected to the controller, wherein the biological parameters comprise one or more of arterial blood pressure, central venous pressure, capillary pressure, systolic pressure variation, arterial blood gases, cardiac output, systemic vascular resistance, pulmonary artery wedge pressure, and mixed venous oxygen saturation, wherein the controller

adjusts the therapy signal delivered by the therapy delivery device in response to the one or more sensor signals.

2. The device of claim 1, wherein the plurality of electrodes serve as cathodes and the collapsible frame serves as an anode.

3. The device of claim 1, wherein the collapsible frame comprises a superelastic material.

4. The device of claim 3, wherein the superelastic material comprises nitinol.

5. The device of claim 1, wherein the frame comprises an open stent-like configuration at a distal end.

6. The device of claim 5, wherein the configuration comprises diamond shapes connected to each other the connectors, sufficient to create the closed circular loop.

7. The device of claim 1, wherein the frame is capable of delivering a bioactive agent prior to, concurrent with or subsequent to electrical modulation.

8. The device of claim 7, where the controller operates one or more drug ports for delivery of bioactive agents.

9. The device of claim 1, wherein the at least one autonomic fiber comprises at least one of sympathetic fibers and parasympathetic fibers.

10. The device of claim 9, wherein the sympathetic fibers comprise one or more of right sympathetic nerves and left sympathetic nerves.

11. The device of claim 10, wherein the right sympathetic nerves comprise one or more of right dorsal medial cardiopulmonary nerves and right dorsal lateral cardiopulmonary nerves.

12. The device of claim 10, wherein the left sympathetic nerves comprise one or more of left ventral cardiopulmonary nerves, left dorsal medial cardiopulmonary nerves, left dorsal lateral cardiopulmonary nerves and left stellate cardiopulmonary nerves.

13. The device of claim 1, wherein each of the plurality of electrodes is annularly disposed on one of the plurality of insulated electrical conductors.

14. A therapy delivery device for treating cardiovascular medical conditions, the therapy delivery device comprising:
  - a plurality of insulated electrical conductors each having a distal end;

- a plurality of electrodes, each said electrode of the plurality of electrodes being in electrical communication with one said insulated electrical conductor of the plurality of insulated electrical conductors, the plurality of electrodes being configured to contact one or more portions of a pulmonary artery of a subject and configured to deliver a therapy signal to at least one autonomic fiber proximate to the pulmonary artery to affect one or more of cardiac output and hemodynamics; and

- a frame connected to the distal ends of the plurality of insulated electrical conductors at a plurality of coupling points, the frame changeable between a first collapsed configuration in a catheter lumen and a second expanded configuration out of the catheter lumen, the plurality of electrodes proximal to the coupling points.

15. The device of claim 14, further comprising:

- a controller in electrical communication with the plurality of electrodes; and

- a sensor configured to measure a biological parameter and to generate sensor signals receivable by the controller.

16. The device of claim 15, wherein the biological parameter comprises one or more of arterial blood pressure, central venous pressure, capillary pressure, systolic pressure varia-

**11**

tion, arterial blood gases, cardiac output, systemic vascular resistance, pulmonary artery wedge pressure, and mixed venous oxygen saturation.

**17.** The device of claim **16**, wherein the controller is configured to adjust the therapy signal delivered by the therapy delivery device in response to the sensor signals. 5

**18.** The device of claim **14**, wherein the plurality of electrodes is spaced from a proximal end of the frame by segments of the plurality of insulated electrical conductors.

**19.** The device of claim **14**, wherein the plurality of electrodes is proximate to a proximal end of the frame. 10

**20.** The device of claim **14**, wherein each of the plurality of electrodes is annularly disposed on one of the plurality of insulated electrical conductors.

\* \* \* \* \*

15

**12**



UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 9,480,790 B2  
APPLICATION NO. : 14/085311  
DATED : November 1, 2016  
INVENTOR(S) : Sandra Machado, Marc Penn and Ali R. Rezai


Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

At Column 9, Line 36, In Claim 1, after “of” insert --the--.

Signed and Sealed this  
Seventh Day of March, 2017

A handwritten signature in black ink, reading "Michelle K. Lee". The signature is written in a cursive style with a long horizontal flourish at the end.

Michelle K. Lee  
*Director of the United States Patent and Trademark Office*